An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana
Top Cited Papers
- 1 April 2004
- journal article
- research article
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 98 (3), 231-249
- https://doi.org/10.1179/000349804225003253
Abstract
If ivermectin-based programmes for the control of human onchocerciasis are to be successful, the drug must remain effective for as long as necessary. In an open, case-control study, an attempt was made to determine if the persistent, significant, Onchocerca volvulus microfilaridermias seen in some individuals who had received at least nine treatments with ivermectin were the result of the development of drug resistance in the parasite. Twenty-one of these 'sub-optimal' responders (cases) were matched, by age, weight, number of treatments, locality and skin microfilarial counts, with seven amicrofilaridermic responders and 14 ivermectin-naive subjects. The number of treatments taken, any potential drug interactions and significant underlying disease were determined from detailed clinical and laboratory studies. Each subject was treated with ivermectin during the study, so that plasma concentrations of the drug could be determined for 72 h from the time of dosage. The microfilarial and adult-worm responses to this treatment were assessed from skin microfilarial counts (obtained before the treatment and at days 8, 90 and 365 post-treatment), day-90 embryogrammes, and the results of fly-feeding experiments. Parasite-sensitivity criteria for various time-points were derived from earlier data on skin microfilaridermias and the effects of ivermectin on the adult worms. The results indicate that the significant microfilaridermias that persist despite multiple treatments with ivermectin are mainly attributable to the non-response of the adult female worms and not to inadequate drug exposure or other factors. The possibility that some adult female worms have developed resistance to ivermectin cannot be excluded. These results justify the routine monitoring of treatment efficacy in any ivermectin-based programme of disease control.Keywords
This publication has 15 references indexed in Scilit:
- Final report of the Conference on the eradicability of OnchocerciasisFilaria Journal, 2003
- Immunocompetence may be important in the effectiveness of Mectizan® (ivermectin) in the treatment of human onchocerciasisActa Tropica, 2002
- The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients.Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999
- La résistance de Onchocerca volvulus à livermectine: une éventualité à considérerAnnales de l'Institut Pasteur / Actualités, 1999
- The impact of Mectizan on the transmission of onchocerciasis.Pathogens and Global Health, 1998
- Economic impact of onchocerciasis through the African Programme Onchocerciasis Control: control for an overviewPathogens and Global Health, 1998
- The safety and efficacy of amocarzine in African onchocerciasis and the influence of ivermectin on the clinical and parasitological response to treatmentPathogens and Global Health, 1997
- The Effects of Repetitive Community-Wide Ivermectin Treatment on Transmission of Ochocerca Volvulus in GuatemalaThe American Journal of Tropical Medicine and Hygiene, 1992
- Effects of Three-Month Doses of Ivermectin on Adult Onchocerca VolvulusThe American Journal of Tropical Medicine and Hygiene, 1992
- The chemotherapy of onchocerciasis IIPathogens and Global Health, 1980